

Providing Sustainable Products, Education And Technical Support



Summary

Why It Matters:

We are a veterinary pharmaceutical company; our priority is the health and welfare of animals and everything we do is with this priority in mind.

Our Objectives:

- Develop and promote products to improve animal health and welfare sustainably
- Maintain and improve the knowledge and skills of veterinarians
- Act with honesty and integrity

Our Performance:

- 7.8% of revenue invested in R&D
- 85,865 of CPD hours provided globally
- Value chain sustainability assessment ongoing, with 77 entities assessed this year

Develop And Promote Products To Improve Animal Health And Welfare Sustainably

The development of innovative new products that sustainably improve animal health and welfare is closely aligned to our Purpose and fundamental to our future success. Our pipeline of products are targeted at providing veterinary professionals with solutions for their clinical needs, particularly with regards to unmet or under serviced cases seen in companion animals.

Delivering a strong and robust pipeline with a focus on novelty remains one of our strategic objectives, and our investment in R&D has increased significantly over the past two years. We spent £62.3 million this year, representing 7.8% of revenue, a record amount for Dechra. Most of this spend relates to the development of small molecules, many of which have already been developed for use in human health and for which we are now exploring possible applications in animals.

In December 2023, we acquired a 20% stake in 272Bio Limited, a business which develops biotherapeutics for livestock and companion animal disorders using innovative technologies.

We achieved a number of product approvals during the year, most notably a divisible Vetoryl tablet for the EU market and a Felimazole liquid. These new product registrations help to expand the reach of our portfolio to help treat even more animals worldwide.


After the financial year end, Dechra completed the largest transaction in its history with the acquisition of Invetx Inc, a Boston based biotechnology company specialising in long acting monoclonal antibodies (mAbs) for companion animals.

The acquisition underscores our ambition to be an innovation leader in companion animal health by securing a pipeline of innovative products in therapeutic areas such as atopic dermatitis and osteoarthritis, making them highly complementary to our existing portfolio. We are excited by the future potential of this pipeline and the new technology capability now at our disposal.


Maintain And Improve The Knowledge And Skills Of Veterinarians

Our relationship with veterinarians is crucial to our business. As such, we provide added value services in the form of educational programmes and technical support to maintain and improve the knowledge and skills of veterinarians who prescribe and use our products. These services are designed to be highly complementary to the broad range of products that we offer, and help us to become the partner of choice with veterinarians in the therapeutic areas in which we operate.

R&D Investment



Applicable UN SDGs



Providing Sustainable Products, Education And Technical Support continued



Our Business

Educational Programmes

We deliver education through many channels, including conferences, practice meetings, lunch and learns, and our online digital e-learning environment, the Dechra Academy. Veterinary professionals are able to claim continuous professional development (CPD) (or continuous education (CE) in the US) points towards maintaining their qualifications by attending our events, making them highly attractive.

The Dechra Academy helps veterinary professionals across the globe to expand their knowledge and keep up-to-date with the latest thinking through completely free, engaging learning experiences. With over ten years of experience educating veterinary professionals, we are passionate and proud to provide reputable, modern learning resources which help veterinary professionals continuously evolve their knowledge. We organise a number of educational events and webinars throughout the year covering a range of therapeutic subject matters, for example dermatology and endocrinology, where we are regarded as the market leader.

We differentiate ourselves from our competitors by focusing on challenging and interactive educational experiences. Each Dechra market has its own tailored Academy with courses that are relevant to their veterinary professionals and, where possible, our educational resources are accredited by local professional and regulatory bodies.

We now have a total of 124,000 registered users (2023: 109,691) and 1,888 individual courses (2023: 945) on the Dechra Academy, which is available in 27 markets.

During the year, we provided 17,424 hours of CDP via our Dechra Academy and a further 72,441 hours of in-person training events.

Technical Support

We offer a wide range of products, including several that treat complex and less frequently occurring disorders such as Cushing's and Addison's disease, which can be treated through our products Vetoryl® and Zycortal® respectively. The provision of high quality technical support on these products is a service that the veterinarians truly value, evidenced by the sheer number of calls made to our technical support line last year.

Act With Honesty And Integrity

As part of our commitment to acting with honesty and integrity, we have pursued a number of initiatives geared toward building a clear picture of how we work with suppliers, partners and customers across our value chain.

The scope of this work is very broad, encompassing many different parts of the business such as:

- third party due diligence and compliance tools when onboarding new suppliers;
- engagement with veterinary customers on our respective sustainability ambitions during tender processes;
- integrating sustainability into product development stages;
- integrating responsible sourcing into CAPEX reviews; and
- working towards more strategic partnerships with third party CMOs.

Despite no longer being a listed business, we will remain transparent and are committed to continue the publication of an annual Sustainability Report. We have also implemented a new governance framework to support the delivery of our new Sustainability strategy. See page 41 for further details.

Case Study

Launch Of Connect

We are widely regarded as the experts in endocrinology, providing an extensive range of information to assist veterinarians in the diagnosis, treatment, and monitoring of endocrine diseases.

However, this information has traditionally been dispersed across multiple brochures, websites, and other materials and we were conscious that having information in different places makes it challenging for veterinarians to locate specific resources and doesn't provide the best customer experience.

In response to this, we were delighted this year to launch Cushing's Connect and Addison's Connect; our two new digital platforms specifically designed for veterinarians. These platforms serve as comprehensive consolidated information hubs for veterinarians in need of assistance with diagnosing and treating patients suffering from Cushing's or Addison's.

